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FIRST ANALYSIS OF HUMAN HERPESVIRUS 6 T-CELL RESPONSES:
SPECIFIC BOOSTING AFTER HHV6 REACTIVATION IN STEM CELL
TRANSPLANTATION RECIPIENTS
de Pagter, P.J.A.1, Boelens, J.J.1, Scherrenburg, J.S.2, Vroom-de
Blank, T.3, Tesselaar, K.2, Nanlohy, N.N.2, Sanders, E.A.M.1,
Schuurman, R.3, van Baarle, D.2 1UMC Utrecht, Netherlands; 2UMC
Utrecht, Netherlands; 3UMC Utrecht, Netherlands
Background: Human herpes virus 6 (HHV6) reactivation after he-
matopoietic stem cell transplantation (HSCT) is associated with
acute-Graft-versus-host-disease (aGvHD) and poor survival. Char-
acterization of HHV6 immune responses is essential to develop
HHV6-specific (immuno) therapy and to elucidate the association
with aGvHD.
Methods: Prospectively, HHV6 DNA-load was weekly measured
by realtime-PCR. HHV6-reactivation was defined as DNA-load .
1000cp/mL. Alloreactive disease was defined as aGvHD and/or idi-
opathic pulmonary syndrome. T-cell reconstitution was measured
by immunophenotyping. Numbers of IFNg-producing HHV6-
T-cells in peripheral blood mononuclear cells (PBMC) 2 months
after HSCT were retrospectively determined by enzyme-linked
immunospot (ELIspot) assay. HHV6-specific T-cell proliferative
capacity after HSCTwas analyzed using a newly developed assay us-
ing autologous HHV6-infected PBMC.
Results: Fifty-six patients were included (median age 4.6 years;
range 0.2-21.2 yrs) with a median followup of 30 months (range
0-30). All patients received myeloablative conditioning and stan-
dardized graft-versus-host disease prophylaxis. During follow-
up, 29/56 (52%) patients developed HHV6-reactivation with
a median time of reactivation of 14 (range 1-41) days. In total,
13/56 (23%) of patients developed alloreactive disease during fol-
lowup. In all cases, HHV6 reactivation preceded the alloreactive
disease. No difference in overall T-cell numbers was observed be-
tween patients with or without HHV6-reactivation. The median
number of Interferon-g producing HHV6-specific T-cells at 2
months and the HHV6-specific CD81T-cell proliferative capac-
ity at 6 months after HSCT were increased after HHV6-reactiva-
tion compared to non-reactivating patients (P 5 0.006 and p 5
0.036, respectively).
Conclusion: HHV6-specific T-cell responses were specifically in-
creased after HHV6-reactivation, despite comparable numbers of
total T-cells. Although overall T-cell numbers are extremely low
early after HSCT, these analyses show a clear anti-viral response.
This identification of HHV6-specific T-cell responses early after
HSCT is essential to develop antiviral immunotherapy, to booster
these responses to prevent reactivation after HSCT. This first anal-
ysis of HHV6-specific T-cells may contribute to unravel the role of
HHV6-reactivation in the development of aGvHD.209
EARLY LYMPHOCYTE RECOVERY POST UNRELATED HEMATOPOIETIC
STEM CELL TRANSPLANT (UHSCT) IS ASSOCIATED WITH BETTER SUR-
VIVAL AND LESS ACUTE GRAFT VERSUS HOST DISEASE (aGVHD)
Gul, Z.1, Ditah, I.2, Abdul-Hussein, M.3, Deol, A.1, Ayash, L.1,
Abidi, M.1, Lum, L.1, Uberti, J.1, Rratanatharathorn, V.1,
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Background: UHSCT is associated with significant morbidity and
mortality. Graft versus host disease and infections are significant
contributing factors. Early lymphocyte recovery has been associated
with improved outcomes inmatched sibling transplants; however the
same association is unclear in UHSCT.
Methods: We retrospectively evaluated a cohort of consecutive
UHSCT patients for transplant outcomes as well as absolute lym-
phocyte recovery at day 30 post transplant (ALC 30). Patients
were transplanted between January 2006 and June 2010 at Karma-
nos Cancer Center, and received Mycophenolate Mofetil and
Tacrolimus for GVHD prophylaxis (N 5 154). We performed
a multivariate analysis to determine predictors of ALC 30 as
well as impact of ALC 30 ($ or\ than 400  106/L) on the in-
cidence of aGVHD, cGVHD, CMV reactivation, relapse and
overall survival.Results: The median age was 52 years, (Interquartile range IQR
21-64). Disease diagnoses were: AML41%, MDS 12%, ALL
13%, CML 4.5%, DLBCL 4.5%, CLL 5.2%, MCL 5.2%. Disease
status at transplant was: First complete remission (CR1) 23.7%,
CR2 11.8%, relapsed or progressive disease 47%, and untreated
disease 12.5%. Conditioning regimens included Bu/Flu 43%, Bu/
Flu/TBI 17%, R-BEAM 11%, Flu/Mel/TBI 8%, VP16/TBI 7%,
and Cy/TBI 6.5%. HLA Match status was: 10/10 58%, 9/10
32%, 8/10 9%, and 7/10 1%. The median CD 341 count was
7.4 million/Kg (IQR 5.34-9.69). Donors were 65% males with
a median age of 31 yrs (IQR 19-53). CMV status of donors was
positive in 43%, compared to 53% of recipients. The incidence
of ALC 30 $ 400  106/L was 68% (N 5 97), aGVHD grade
II-IV 53% (N 5 82), cGVHD 53.3% (N 5 81), CMV reactivation
32% (N 5 49), and relapse 13.25% (N 5 20). At a median follow
up of 339 (109-891) days, 48% of patients were alive. In multivar-
iate analysis, CMV status, age, gender of donor and recipient,
CD341 cell count, degree of mismatch or disease status were
not significant predictors of ALC 30. ALC 30 $ 400  106/L
was significantly associated with decreased risk of mortality (HR
0.22, CI 0.11-0.44; P 5 0.0001) and reduction in the risk of subse-
quent aGVHD (P 5 0.01). ALC 30 $ 400  106/L was not found
to predict less incidence of cGVHD (P 5 0.59), CMV reactivation
(P 5 0.123), or relapse (P 5 0.93).
Conclusion: The above results demonstrate that higher day 30 ab-
solute lymphocyte recovery can predict better overall survival and
less aGVHD in UHSCT.
Table 1. Absolut Lymphocyte CountDay 30 (ALC 30) Predicts
Clinical Outcomes in UHSCT
Hazard Confidence
Clinical Outcome Ratio HR P value interval CIMortality 0.22 0.001 0.11-0.44
Acute GVHD 0.09 0.018 0.01-0.66
Chronic GVHD 1.26 0.593 0.53-3.03
CMV reactivation 0.48 0.123 0.19-1.21
Relapse 1.09 0.933 0.14-8.16210
IMMUNE RECONSTITUTION AFTER NONMYELOABLATIVE, T-CELL
REPLETE, HLA-HAPLOIDENTICAL BMT WITH POST-TRANSPLANTATION
CYCLOPHOSPHAMIDE
Kesserwan, C.1, Munchel, A.1, Kos, F.2, Thoburn, C.2, Hess, A.2,
Luznik, L.2, Kasamon, Y.2, Levitsky, H.2, Jones, R.2, Fuchs, E.J.2,
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Delayed immune reconstitution with increased risk of opportunis-
tic infection is a major complication ofHLA-haploidentical stem cell
transplantation, especially in protocols employing extensive T cell
depletion of the graft. Here we characterize phenotypic immune re-
constitution in hematologic malignancies patients receiving non-
myeloablative conditioning, T cell-replete, HLA-haploidentical
bone marrow transplantation (BMT), and graft versus host disease
(GVHD) prophylaxis including high-dose, post-transplantation
cyclophosphamide (Cy). Patients with advanced hematologic malig-
nancies (median age 45, range 29-69; 3 AML, 1 bilineage leukemia, 1
ALL, 1 MDS, 1 CML, 1 CLL, 1 CMML, 7 NHL, 4 Hodgkins, 1
mantle cell) receivedCy 14.5mg/kg/day IV on days -6 and -5, fludar-
abine 30 mg/m2/day IV on days -6 to -2, 200 cGy of TBI on day -1
and T cell replete bone marrow from donors with a median age of 44
(range 14-68). GVHD prophylaxis consisted of Cy (50 mg/kg/day)
on days 3 and 4, mycophenolate mofetil for 30 days, and tacrolimus
for 6 months. Grafts contained an infused median TNC/kg of 4.1e8
(range 3.1-5.4 e8), CD31/kg 3.8e6 (range 1.7-8.8e6) and a CD341/kg
of 3.8e7 (range 1.54-6.2e7). Donor engraftment occurred in 81% of
patients (17/21). The median times to neutrophil (. 500/mL) and
platelet recovery (. 20,000/mL) are 17 days (range, 13-92 days)
and 30 days (range, 14-580 days), respectively. Post-transplantation
recovery of lymphocyte subsets is shown in Table 1 and is notable for
the following: 1) The median lymphocyte count at day 30 after
